Cargando…

Correction to: Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use

Detalles Bibliográficos
Autor principal:	Lyseng-Williamson, Katherine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061529/ https://www.ncbi.nlm.nih.gov/pubmed/31186612 http://dx.doi.org/10.1007/s40267-018-0534-y

Ejemplares similares

Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use
por: Lyseng-Williamson, Katherine A.
Publicado: (2017)

Correction: Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
por: Aravena, Carlos, et al.
Publicado: (2015)

Correction to: Anakinra in Still’s disease: a profile of its use
por: Lyseng‑Williamson, Katherine A.
Publicado: (2018)

Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Correction to: Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
por: Lyseng-Williamson, Katherine A.
Publicado: (2019)

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
por: Lyseng-Williamson, Katherine A.
Publicado: (2020)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
por: Takehara, Kazutaka, et al.
Publicado: (2022)

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Valeyre, Dominique, et al.
Publicado: (2014)

Pirfenidone-Induced Photosensitivity in a Patient with Idiopathic Pulmonary Fibrosis
por: Kim, Ho-Jin, et al.
Publicado: (2018)

Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
por: Alhamad, Esam H.
Publicado: (2015)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
por: Salih, Goran Nadir, et al.
Publicado: (2016)

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
por: Ren, Hui, et al.
Publicado: (2017)

Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone
por: Kubbara, Aahd, et al.
Publicado: (2023)

Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey
por: Lancaster, Lisa H., et al.
Publicado: (2020)

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?
por: Dhooria, Sahajal, et al.
Publicado: (2015)

Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
por: Aravena, Carlos, et al.
Publicado: (2015)

Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models
por: Yu, Wencheng, et al.
Publicado: (2016)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2017)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
por: Belhassen, Manon, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
por: Rinciog, C., et al.
Publicado: (2020)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
por: Kaushal, Mohit, et al.
Publicado: (2022)

Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2018)

The Efficacy and Safety of Long-term Pirfenidone Therapy in Patients with Idiopathic Pulmonary Fibrosis
por: Ogawa, Kazumasa, et al.
Publicado: (2018)

Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients
por: Huang, Hui, et al.
Publicado: (2015)

Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
por: Sakayori, Masashi, et al.
Publicado: (2019)

Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
por: Gulati, Swati, et al.
Publicado: (2020)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3oqc45cu3olvr3ggu0in3uupia